Aprea Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aprea Therapeutics has been growing earnings at an average annual rate of 37.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 127.2% per year.
Key information
37.5%
Earnings growth rate
58.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 127.2% |
| Return on equity | -58.1% |
| Net Margin | -1,030.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Aprea Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -14 | 7 | 0 |
| 30 Jun 24 | 1 | -13 | 7 | 0 |
| 31 Mar 24 | 1 | -13 | 7 | 0 |
| 31 Dec 23 | 1 | -14 | 8 | 0 |
| 30 Sep 23 | 1 | -13 | 9 | 0 |
| 30 Jun 23 | 0 | -14 | 6 | 0 |
| 31 Mar 23 | 0 | -109 | 20 | -4 |
| 31 Dec 22 | 0 | -113 | 21 | 0 |
| 30 Sep 22 | 0 | -118 | 22 | 4 |
| 30 Jun 22 | 0 | -123 | 26 | 10 |
| 31 Mar 22 | 0 | -35 | 14 | 21 |
| 31 Dec 21 | 0 | -37 | 14 | 0 |
Quality Earnings: APRE is currently unprofitable.
Growing Profit Margin: APRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APRE is unprofitable, but has reduced losses over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare APRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APRE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: APRE has a negative Return on Equity (-58.08%), as it is currently unprofitable.